Drug Discovery and One Health Approach in Combating Infectious Diseases

Kanti Bhooshan Pandey is a Principal Scientist and Assistant Professor in the Faculty of Biological Sciences, Academy ofScientific and Innovative Research (AcSIR); CSIR-Central Salt & Marine Chemicals Research Institute, Gujarat, India. Prof. David J. Newman is currently an NIH Special Volunteer. He holds a research MSc (1963, organic chemistry, Univ. Liverpool, UK), a DPhil (1968, microbiological chemistry, Univ. Sussex UK), followed by a 2 yr post-doc at the Univ. Georgia (USA) on rubredoxin sequencing, and an MLS (1977, Drexel Univ., USA). After the post-doc He spent 15 years at SKF (now GSK) in the US mainly in antibiotic discovery, then six years in smaller companies still in the USA, mainly dealing with marine chemistry and then in 1991 joined the Natural Products Branch of the NCI covering marine and microbial sources as leads to antitumor drugs. When Gordon Cragg retired as Branch Chief at the end of 2004, he became Branch Chief, retiring in early January 2015. He now is an NIH Special Volunteer (honorary position) with the same branch. He has published over 240 papers/chapters, has held adjunct and honorary positions as a full Professor at the University of Maryland (USA) and at MacQuarrie University in Sydney, Australia (still active). He still publishes on natural products mainly from marine and microbial sources. He is currently a Fellow of the Royal Society of Chemistry and a Chartered Chemist, also a Fellow of the Royal Society of Biology and a Chartered Biologist. He is also Fellow of the American Society of Pharmacognosy and last year he was made an honorary member of that society. He is also an emeritus member of both the American Society of Microbiology and the American Chemical Society.Chukwuebuka Egbuna (PhD) is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Dr. Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs, and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited more than 25 books with Elsevier, Springer, Wiley, and Taylor & Francis. His most recent book is the three volume Coronavirus Drug Discovery, published by Elsevier. Dr. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services.

• Part I: Introduction and Basics1. Introduction to Drug Discovery and One Health Approach2. Fundamentals of Infectious Diseases and Global Health ThreatsPart II: One Health Framework3. The Concept of One Health4. Zoonotic Diseases and their Implications5. Role of Surveillance and EpidemiologyPart III: Drug Discovery Process6. Overview of Drug Discovery and Development Process7. Target Identification and Validation in Drug Discovery8. High-Throughput Screening and Rational Drug DesignPart IV: Approaches to Drug Development9. Traditional Medicinal Plants and Natural Compounds in One Health approach10. Antibiotics and Antiviral Agents11. Vaccines as Preventive MeasuresPart V: Advanced Technologies in Drug Discovery12. Genomics and Proteomics13. Structural Biology and Computer-Aided Drug Design14. Nanotechnology and Drug Delivery SystemsPart VI: One Health in Action15. Case Studies of Successful Approaches16. Collaboration and Challenges Between Medical and Veterinary Professionals in One Health Implementation17. Environmental Factors and Disease TransmissionPart VII: Regulatory and Ethical Considerations18. Regulatory Pathways for the Development of Drugs and Vaccines19. Ethical Considerations in One Health Research20. Future Prospects: Emerging Technologies